BEAD-T1D: Building the Evidence to Address Disengagement in Type 1 Diabetes
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT Number: NCT02750527
This is a Pilot/ feasibility study for a population-based Screening in all children 2 to 6 years in Lower Saxony, Germany during the compulsory (U7 (from the age of 2) U7a, U8, U9) routine check-ups and any voluntary visits to the pediatricians office.
Looking for future studies?
Notify Me2 year–6 year
All sexes
Observational
The Fr1dolin-Study will be presented to the parents of ca. 320,000 children living in Lower Saxony, Germany. The recruitment of subjects, collection of written consent, the capillary blood sample and the screening questionnaire will be done by the registered pediatricians in their local medical practices.
After study enrolment 200 µl of capillary blood are be taken from the subject and are sent pseudo-anonymized to the lab. LDL-C and the diabetes-associated antibodies are identified. Based on the results a second blood sample will be required. In case of pre-type-1 diabetes or signs for a familial hypercholesterolemia the pediatrician will be informed. He will contact the parents and discuss the further procedure in cooperation with the study center.
In case of a positive result by measuring diabetes-related antibodies and LDL-C the goal of this trial is to advise and educate the families appropriate and to treat them if necessary. In addition families should have the possibility to participate in prevention trials.
All data will be registered in a study database.
Follow-up pre-type 1 diabetes:
During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years or up to 6 months after the clinical onset of type 1 diabetes.
Follow-up familial hypercholesterolemia:
During the first year, follow-up will be performed after 6 and 12 months and thereafter annually until the age of 12 years.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 18 month
identification of patients/ families with familial hypercholesterolemia or pre-type-1 diabetes
Kinderkrankenhaus auf der Bult
Other
Acronym: Fr1dolin
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05488119
Autoimmune Diseases, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT07696780
Autoimmune Diseases, Diabetes Mellitus
Bern, Canton of Bern, Switzerland
View Trial DetailsNCT05610111
Autoimmune Diseases, Diabetes Mellitus
Charlottesville, Virginia, United States
View Trial DetailsNCT06308549
Autoimmune Diseases, Diabetes Distress
Bad Mergentheim, Baden-Wurttemberg, Germany
View Trial Details